QFR指导冠脉介入的2年结局:FAVOR III China试验
FAVOR III China随机假手术对照试验纳入3825例冠心病患者,比较QFR指导(仅QFR≤0.80行PCI)与造影指导的PCI策略。2年MACE在QFR组8.5%、造影组12.5%(HR 0.66,95%CI 0.54-0.81,P<0.0001),获益主要由心梗和缺血驱动血运重建减少驱动,QFR改变预设策略者获益更显著。
要点
- QFR指导较造影指导降低2年MACE(8.5% vs 12.5%,HR 0.66)
- 获益来自心梗(4.0% vs 6.8%)和缺血驱动血运重建(4.2% vs 5.8%)减少
- QFR改变预设血运重建策略的患者结局改善幅度更大(Pint=0.009)
核心结论
- QFR指导的病变选择较标准造影指导改善2年临床结局,在QFR评估改变预设血运重建策略的患者中获益最显著。
研究设计与样本
- 多中心、随机、假手术对照FAVOR III China试验,纳入3825例冠心病患者,随机接受QFR指导策略(仅QFR≤0.80行PCI)或标准造影指导策略,按意向治疗人群分析2年MACE。
主要发现
- 2年MACE在QFR组161/1913例(8.5%)、造影组237/1912例(12.5%),HR 0.66(95%CI 0.54-0.81),P<0.0001。
- 心梗发生率QFR组4.0%、造影组6.8%,HR 0.58(95%CI 0.44-0.77),P=0.0002。
- 缺血驱动血运重建QFR组4.2%、造影组5.8%,HR 0.71(95%CI 0.53-0.95),P=0.02。
- Landmark分析显示第1年内及1-2年间结果一致(Pint=0.99)。
- 有无血运重建策略改变的患者中QFR组2年MACE均较低,但策略被QFR修改者改善幅度更大(Pint=0.009)。
关键数值与推荐
- QFR指导策略规定仅当QFR≤0.80时行PCI。
- 2年MACE定义为全因死亡、心肌梗死或缺血驱动血运重建的复合终点。
临床怎么用
- 在冠心病PCI血运重建决策中,可采用QFR指导病变选择以改善2年临床结局,尤其当QFR评估改变原造影预设策略时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the multicenter, randomized, sham-controlled FAVOR (Comparison of Quantitative Flow Ratio Guided and Angiography Guided Percutaneous Intervention in Patients with Coronary Artery Disease) III China trial, quantitative flow ratio (QFR)-based lesion selection improved 1-year clinical outcomes compared with conventional angiographic guidance for percutaneous coronary intervention (PCI). OBJECTIVES: The purpose of this study was to determine whether the benefits of QFR guidance persist at 2 years, particularly for patients in whom QFR changed the revascularization strategy. METHODS: Eligible patients were randomized to a QFR-guided strategy (PCI performed only if QFR ≤0.80) or a standard angiography-guided strategy. Major adverse cardiac events (MACE), a composite of all-cause death, myocardial infarction (MI), or ischemia-driven revascularization occurring within 2 years were analyzed in the intention-to-treat population. RESULTS: Among 3,825 randomized participants, 2-year MACE occurred in 161 of 1,913 (8.5%) patients in the QFR-guided group and in 237 of 1,912 (12.5%) patients in the angiography-guided group (HR: 0.66; 95% CI: 0.54-0.81; P < 0.0001), driven by fewer MIs (4.0% vs 6.8%; HR: 0.58; 95% CI: 0.44-0.77; P = 0.0002) and ischemia-driven revascularizations (4.2% vs 5.8%; HR: 0.71; 95% CI: 0.53-0.95; P = 0.02) in the QFR-guided group. Landmark analysis showed consistent results within the first year and between 1-2 years (Pint = 0.99). Although the 2-year MACE rate was lower in the QFR-guided group in both patients with and without revascularization strategy changes, the extent of outcome improvement was greater (Pint = 0.009) among those patients in whom the preplanned PCI strategy was modified by QFR. CONCLUSIONS: QFR-guided lesion selection improved 2-year clinical outcomes compared with standard angiography guidance. The benefits were most pronounced among patients in whom QFR assessment altered the planned revascularization strategy. (FAVOR III China Study [The Comparison of Quantitative Flow Ratio Guided and Angiography Guided Percutaneous Intervention in Patients with Coronary Artery Disease] NCT03656848).
引用
- Song L, Xu B, Tu S, et al. 2-Year Outcomes of Angiographic Quantitative Flow Ratio-Guided Coronary Interventions. J Am Coll Cardiol. 2022. PMID: 36424680. doi:10.1016/j.jacc.2022.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。